Clin Exp Ophthalmol2025Journal Article

Outcomes of Stent Removal in Eyes With the Paul Glaucoma Implant With Intraluminal 6-0 Polypropylene.

Authors

Nicole Shu-Wen Chan, Seah Wei Hing, Naoki Okada, Li Hengtong, Maria Cecilia Aquino, Teck Chang Victor Koh, Katherine Wanxian Lun, Dawn Ka Ann Lim, Paul Tec Kuan Chew, Marcus Chun Jin Tan

IOP & Medical TherapyOCT & Imaging

3 citations

Summary

Less than half of the eyes with PGI stented with intraluminal 6-0 polypropylene required stent removal.

Abstract

BACKGROUND

To evaluate the 12-month outcomes of stent removal in eyes with the Paul Glaucoma Implant (PGI) and intraluminal 6-0 polypropylene in an Asian population.

METHODS

Retrospective review of patients ≥ 18 years of age with glaucoma in a tertiary institution, who underwent the PGI stented with intraluminal 6-0 polypropylene (October 2018 to January 2023), with a minimum follow-up duration of 12 months. The main outcome measures were intraocular pressure (IOP) and number of glaucoma medications.

RESULTS

We included 103 eyes of 97 patients, who were mostly Chinese (73.8%). The stent was removed in 43 eyes (41.7%), at a median of 12.3 (interquartile range: 4.1-18.4) postoperative weeks. The mean IOP reduction immediately following stent removal was -6.4 ± 5.0 mmHg, and there was a strong linear correlation with the IOP before stent removal (Pearson correlation -0.554; p < 0.001). No eyes developed hypotony after stent removal.

CONCLUSIONS

Less than half of the eyes with PGI stented with intraluminal 6-0 polypropylene required stent removal. The IOP reduction achieved after stent removal correlated with the IOP before stent removal, and there were no complications of hypotony.